Program Information

New Potential for Enhancing External Beam Radiotherapy for Lung Cancer Using FDA-Approved Concentrations of Cisplatin Or Carboplatin Nanoparticles Administered Via Inhalation

Y Hao¹* , Y Altundal¹* , E Sajo¹ , A Detappe^2,3,4,5 , G Makrigiorgos^2,3,4 , R Berbeco^2,3,4 , W Ngwa^1,2,3,4 , (1) Univ Massachusetts Lowell, Lowell, MA, (2) Brigham & Woman's Hospital, Boston, MA, (3) Dana Farber Cancer Institute, Boston, MA, (4) Harvard Medical School, Boston, MA, (5) University of Lyon, Lyon, France

Presentations

WE-G-BRE-6 Wednesday 4:30PM - 6:00PM Room: Ballroom E

Purpose: This study investigates, for the first time, the dose enhancement to lung tumors due to cisplatin nanoparticles (CNPs) and carboplatin nanoparticles (CBNPs) administered via inhalation route (IR) during external beam radiotherapy.
Methods: Using Monte Carlo generated 6 MV energy fluence spectra, a previously employed analytic method was used to estimate dose enhancement to lung tumor due to radiation-induced photoelectrons from CNPs administered via IR in comparison to intravenous (IV) administration. Previous studies have indicated about 5% of FDA-approved cisplatin concentrations reach the lung tumor via IV. Meanwhile recent experimental studies indicate that 3.5-14.6 times higher concentrations of CNPs can reach the lung tumors by IR compared to IV. Taking these into account, the dose enhancement factor (DEF) defined as the ratio of the dose with and without CNPs was calculated for field size of 10 cm x 10 cm (sweeping gap), for a range of tumor depths and tumor sizes. Similar calculations were done for CBNPs.
Results: For IR with 3.5 times higher concentrations than IV, and 2 cm diameter tumor, clinically significant DEF values of 1.19-1.30 were obtained for CNPs at 3-10 cm depth, respectively, in comparison to 1.06-1.09 for IV. For CBNPs, DEF values of 1.26-1.41 were obtained in comparison to 1.07-1.12 for IV. For IR with 14.6 times higher concentrations, higher DEF values were obtained e.g. 1.81-2.27 for CNPs. DEF increased with increasing field size or decreasing tumor size.
Conclusions: Our preliminary results indicate that major dose enhancement to lung tumors can be achieved using CNPs/CBNPs administered via IR, in contrast to IV administration during external beam radiotherapy. These findings highlight a potential new approach for radiation boosting to lung tumors using CNPs/CBNPs administered via IR. This would, especially, be applicable during concomitant chemoradiotherapy, potentially allowing for dose enhancement while minimizing normal tissue toxicities.

Contact Email: